ArticleInternational journal of general medicine2025
The Diagnosis and Prognosis Value of Exosomal MascRNA in Patients with Acute Coronary Syndrome.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating exosomal miR-20b-5p and miR-1273g-3p were potential biomarkers for diagnosis and prognosis of acute coronary syndrome.Cardiovascular diagnosis and therapy · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: MascRNA is involved in regulating the immune inflammatory response, but its role in acute coronary syndrome (ACS) remains unclear. This study aims to investigate the diagnostic and prognostic value of plasma exosomal mascRNA for ACS. Methods: A total of 140 ACS patients and 50 patient with non-ACS were enrolled. Exosomes were isolated from plasma utilizing ultracentrifugation, and mascRNA expression in exosomes was quantified by qRT-PCR. Major adverse cardiovascular events (MACEs) occurring during the 1-year follow-up after stent implantation were recorded. The diagnostic value of exosomal mascRNA for ACS was evaluated utilizing receiver operating characteristic (ROC) analysis. The association between exosomal mascRNA level and MACEs was assessed by Kaplan-Meier survival analysis and Cox proportional-hazards regression. Results: Exosomal mascRNA expression was significantly elevated in ACS patients, and positively correlated with Gensini score, white blood cells and age. Exosomal mascRNA demonstrated a diagnostic value for ACS (AUC: 0.763, 95% CI: 0.702-0.824). Combined detection of exosomal mascRNA with cTnI improved the diagnostic preformation for ACS (AUC: 0.866, 95% CI: 0.815-0.916). Exosomal mascRNA expression was higher in patients with MACEs, and patients with high mascRNA exhibited low incidence of MACE-free survival. Cox regression analysis suggested that exosomal mascRNA was independently associated with the risk of MACEs (HR: 3.710, 95% CI: 2.158-6.376, Conclusion: Plasma exosomal mascRNA has the potential to function as a diagnostic biomarker for ACS and as a predictor for the incidence of 1-year MACEs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.